Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair

Nature Communications

Volumn 5, Issue , 2014, Pages

  Sone, Kenbun ^a   Piao, Lianhua ^a   Nakakido, Makoto ^a   Ueda, Koji ^b   Jenuwein, Thomas ^c   Nakamura, Yusuke ^a   Hamamoto, Ryuji ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; CISPLATIN; DOXORUBICIN; GAMMA HISTONE H2AX; HISTONE H2AX; HISTONE METHYLTRANSFERASE; LYSINE; METHYLTRANSFERASE; SMALL INTERFERING RNA; SUPPRESSOR OF VARIEGATION 3-9 HOMOLOGUE 2; UNCLASSIFIED DRUG; CHROMATIN; HISTONE;

ABUNDANCE; CORRELATION; DNA; METHYLATION; MOLECULAR ANALYSIS; MUTATION; PROTEIN;

ARTICLE; BLADDER CANCER; CANCER CELL; CELL VIABILITY; CHEMOSENSITIVITY; CHROMATIN STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FEMALE; GENE SILENCING; HELA CELL LINE; HETEROCHROMATIN; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LUNG CANCER; LUNG PARENCHYMA; MITOSIS; NON SMALL CELL LUNG CANCER; OSTEOSARCOMA; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RADIOSENSITIVITY; REGULATORY MECHANISM; SOFT TISSUE SARCOMA; TANDEM MASS SPECTROMETRY; TISSUE MICROARRAY; UTERINE CERVIX CANCER; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; CELL SEPARATION; CHEMISTRY; CHLOROCEBUS AETHIOPS; CHROMATIN; COS 1 CELL LINE; DNA DAMAGE; DOMINANT GENE; FIBROBLAST; FLOW CYTOMETRY; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; METHYLATION; MOUSE; MUTATION; PHOSPHORYLATION;

ANIMALS; CELL SEPARATION; CERCOPITHECUS AETHIOPS; CHROMATIN; COS CELLS; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; FIBROBLASTS; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION REGULATION; GENES, DOMINANT; HELA CELLS; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYSINE; METHYLATION; MICE; MUTATION; PHOSPHORYLATION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS;

EID: 84923101475     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6691     Document Type: Article

References (64)

1. Moore, J. D. & Krebs, J. E. Histone modifications and DNA double-strand break repair. Biochem. Cell Biol. 82, 446-452 (2004).
2. Lowndes, N. F. & Toh, G. W. DNA repair: the importance of phosphorylating histone H2AX. Curr. Biol. 15, R99-R102 (2005).
3. Pinto, D. M. & Flaus, A. Structure and function of histone H2AX. Subcell. Biochem. 50, 55-78 (2010).
4. Bartova, E., Krejci, J., Harnicarova, A., Galiova, G. & Kozubek, S. Histone modifications and nuclear architecture: a review. J. Histochem. Biochem. 56, 711-721 (2008).
5. Bonner, W. M. et al. GammaH2AX and cancer. Nat. Rev. Cancer 8, 957-967 (2008).
6. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868 (1998).
7. Harper, J. W. & Elledge, S. J. The DNA damage response: ten years after. Mol. Cell 28, 739-745 (2007).
8. Celeste, A. et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat. Cell Biol. 5, 675-679 (2003).
9. Celeste, A. et al. Genomic instability in mice lacking histone H2AX. Science 296, 922-927 (2002).
10. Messick, T. E. & Greenberg, R. A. The ubiquitin landscape at DNA doublestrand breaks. J. Cell Biol. 187, 319-326 (2009).
11. Stewart, G. S. et al. The RIDDLE syndrome protein mediates a ubiquitindependent signaling cascade at sites of DNA damage. Cell 136, 420-434 (2009).
12. Mailand, N. et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131, 887-900 (2007).
13. Doil, C. et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136, 435-446 (2009).
14. Pan, M. R., Peng, G., Hung, W. C. & Lin, S. Y. Monoubiquitination of H2AX protein regulates DNA damage response signaling. J. Biol. Chem. 286, 28599-28607 (2011).
15. Bassing, C. H. et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc. Natl Acad. Sci. USA 99, 8173-8178 (2002).
16. Fernandez-Capetillo, O., Lee, A., Nussenzweig, M. & Nussenzweig, A. H2AX: the histone guardian of the genome. DNA Repair 3, 959-967 (2004).
17. McKinnon, P. J. & Caldecott, K. W. DNA strand break repair and human genetic disease. Annu. Rev. Genomics Hum. Genet. 8, 37-55 (2007).
18. Jeggo, P. A. & Lobrich, M. DNA double-strand breaks: their cellular and clinical impact? Oncogene 26, 7717-7719 (2007).
19. Allis, C. D. et al. New nomenclature for chromatin-modifying enzymes. Cell 131, 633-636 (2007).
20. O'Carroll, D. et al. Isolation and characterization of Suv39h2, a second histone H3 methyltransferase gene that displays testis-specific expression. Mol. Cell Biol. 20, 9423-9433 (2000).
21. Garcia-Cao, M., O'Sullivan, R., Peters, A. H., Jenuwein, T. & Blasco, M. A. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 36, 94-99 (2004).
22. Peters, A. H. et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107, 323-337 (2001).
23. Daury, L. & Trouche, D. Analysis of histone deposition on specific DNA elements in living mammalian cells. BioTechniques 35, 326-332 (2003).
24. Gertych, A., Oh, J. H., Wawrowsky, K. A., Weisenberger, D. J. & Tajbakhsh, J. 3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models. BMC Pharmacol. Toxicol. 14, 11 (2013).
25. Ayrapetov, M. K., Gursoy-Yuzugullu, O., Xu, C., Xu, Y. & Price, B. D. DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. Proc. Natl Acad. Sci. USA 111, 9169-9174 (2014).
26. Sun, Y. et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat. Cell Biol. 11, 1376-1382 (2009).
27. Sedelnikova, O. A. & Bonner, W. M. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 5, 2909-2913 (2006).
28. Nagelkerke, A. et al. Constitutive expression of gamma-H2AX has prognostic relevance in triple negative breast cancer. Radiother. Oncol. 101, 39-45 (2011).
29. Brunner, A. H. et al. Expression of gamma-H2AX in endometrial carcinomas: an immunohistochemical study with p53. Gynecol. Oncol. 121, 206-211 (2011).
30. Matthaios, D. et al. gamma-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. OncoTargets Ther. 5, 309-314 (2012).
31. Jackson, J. P., Lindroth, A. M., Cao, X. & Jacobsen, S. E. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 416, 556-560 (2002).
32. Dickey, J. S. et al. H2AX: functional roles and potential applications. Chromosoma 118, 683-692 (2009).
33. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193-204 (2008).
34. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004).
35. Kao, J. et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr. Cancer Drug Targets 6, 197-205 (2006).
36. Redon, C. E. et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 16, 4532-4542 (2010).
37. Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C. & Durkacz, B. W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63, 6008-6015 (2003).
38. Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320 (2005).
39. Taneja, N. et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J. Biol. Chem. 279, 2273-2280 (2004).
40. Kao, J., Lavaf, A., Lan, C. & Fu, S. Inhibition of gamma-H2AX after ionizing radiation as a biological surrogate of impaired upstream DNA damage signaling and radiosensitivity. J. Cancer Mol. 5, 49-54 (2010).
41. Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428-430 (2011).
42. Chaudhuri, L. et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 99, 688-696 (2014).
43. Huntoon, C. J. et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 73, 3683-3691 (2013).
44. Prevo, R. et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 13, 1072-1081 (2012).
45. Vavrova, J. et al. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat. Environ. Biophys. 52, 471-479 (2013).
46. Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6, 731-740 (2004).
47. Hamamoto, R. et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97, 113-118 (2006).
48. Cho, H. S. et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 14, 476-486 (2012).
49. Takawa, M. et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res. 72, 3217-3227 (2012).
50. Cho, H. S. et al. Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat. Commun. 3, 1072 (2012).
51. Cho, H. S. et al. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 71, 1-6 (2011).
52. Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298-1305 (2011).
53. Kogure, M. et al. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G/S transition. Cancer Lett. 336, 76-84 (2013).
54. Toyokawa, G. et al. Histone lysine methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 is involved in human carcinogenesis through regulation of the Wnt Pathway. Neoplasia 13, 887-898 (2011).
55. Toyokawa, G. et al. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev. Res. (Phila.) 4, 2051-2061 (2011).
56. Toyokawa, G. et al. Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol. Cancer 10, 65 (2011).
57. Unoki, M. et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 101, 98-105 (2009).
58. Cho, H. S. et al. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 13, 676-684 (2011).
59. Hayami, S. et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574-586 (2011).
60. Hayami, S. et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol. Cancer 9, 59 (2010).
61. Cho, H. S. et al. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int. J. Cancer 131, E179-E189 (2012).
62. Kang, D. et al. The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer 52, 126-139 (2013).
63. Kogure, M. et al. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia 15, 1251-1261 (2013).
64. Yoshimatsu, M. et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int. J. Cancer 128, 562-573 (2011).